Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
about
Differential effects of tamoxifen and anastrozole on optic cup size in breast cancer survivors.Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to considerGnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients.Use of disease-modifying antirheumatic drugs during pregnancy and risk of preeclampsia.Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future DirectionsLong-term toxic effects of adjuvant chemotherapy in breast cancer.The role of thymidine kinase in cancer diseases.Advances in the approach to novel drug clinical development for breast cancer.Biomedical applications of trastuzumab: as a therapeutic agent and a targeting ligand.Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis.Azaepothilone B and its derivatives: a patent review.Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors.Harnessing benefit from targeting tumor associated carbohydrate antigens.Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer.Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?Prognostic assessment and adjuvant treatment strategies within early-stage, sporadic triple negative breast cancer patients.Prevalence of Outpatient Cancer Treatment in the United States: Estimates from the Medical Panel Expenditures Survey (MEPS)
P2860
Q33270673-2A5D152E-141B-4F9F-8E82-BDCD4A462A23Q33647335-070D6023-8A9B-413C-9F07-AE285CE59F1AQ34325583-10F73DD8-AC65-45B8-B5AA-70CCCEC79428Q35583779-D36BD063-9C1D-4CA8-8A44-0BEEABA56800Q36393294-594FA521-FE51-4981-BD14-0B7F089E6BC5Q36446926-9C7CE16E-8645-4EF5-87A4-BF07DCF88284Q36629854-39A0B201-AFBC-4FC1-B893-25AAB0CC7716Q37834884-9D0E7C3E-69F4-45A5-91E7-00F2E0F04032Q38088840-0087571A-6109-4F31-A53F-1BDBCF05E95BQ38206546-C8D3B7C0-56FD-414B-8454-0C30CE507E8BQ38408138-0A3C190F-9A13-4CA9-A73D-45F30A242C05Q38452866-28616FE0-B6FB-4340-94D7-87CB6B0F8DEBQ38860410-96D0331C-6956-4884-976B-0ED2CCEFAE5BQ38975455-5EE5922C-B12D-450A-A371-6E67C16FADBBQ39032812-A9BE3FF8-D8F9-4BE2-81A0-A23E53C1B0B4Q46528079-5FE61C5D-0582-42D0-AECC-2FE97038EF84Q51905406-050129ED-1013-48E3-AE1D-1F35A1664C80Q51912002-A3FBEAE6-413F-4C03-9714-7C38E831EBE6Q54618083-DD8CF356-A11E-4A2F-8EFB-A5225AE6A2A8Q57991279-75112C0A-D554-4959-992A-E251A684818C
P2860
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
@ast
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
@en
type
label
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
@ast
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
@en
prefLabel
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
@ast
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
@en
P2093
P1433
P1476
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era
@en
P2093
Chantal Bernard
Mariantonietta Colozza
Martine J Piccart
P304
P356
10.1634/THEONCOLOGIST.11-2-111
P577
2006-02-01T00:00:00Z